BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37394969)

  • 1. Effect of hydroxyurea on erythrocyte apoptosis in hemoglobinopathy patients.
    Kargutkar N; Nadkarni A
    Expert Rev Hematol; 2023; 16(9):685-692. PubMed ID: 37394969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
    Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
    Ballas SK; Connes P;
    Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
    Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
    Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
    Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
    Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia.
    Orringer EP; Blythe DS; Johnson AE; Phillips G; Dover GJ; Parker JC
    Blood; 1991 Jul; 78(1):212-6. PubMed ID: 1712641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
    Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
    Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of microRNA in hydroxyurea mediated HbF induction in sickle cell anaemia patients.
    Kargutkar N; Sawant-Mulay M; Hariharan P; Chandrakala S; Nadkarni A
    Sci Rep; 2023 Jan; 13(1):369. PubMed ID: 36611033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
    Borba R; Lima CS; Grotto HZ
    J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease.
    Hebert N; Rakotoson MG; Bodivit G; Audureau E; Bencheikh L; Kiger L; Oubaya N; Pakdaman S; Sakka M; Di Liberto G; Chadebech P; Vingert B; Pirenne F; Galactéros F; Cambot M; Bartolucci P
    Am J Hematol; 2020 Nov; 95(11):1235-1245. PubMed ID: 32681733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome.
    Ghatpande SS; Choudhary PK; Quinn CT; Goodman SR
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1510-7. PubMed ID: 18849548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
    Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia.
    Fibach E; Burke LP; Schechter AN; Noguchi CT; Rodgers GP
    Blood; 1993 Mar; 81(6):1630-5. PubMed ID: 7680923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia.
    Yahouédéhou SCMA; da Guarda CC; Figueiredo CVB; Santiago RP; Carvalho SP; Fiuza LM; Ndidi US; Oliveira RM; Carvalho MOS; Nascimento VML; Rocha LC; Lyra IM; Adorno EV; Goncalves MS
    PLoS One; 2019; 14(7):e0218040. PubMed ID: 31306416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Potential alternatives to erythrocyte transfusion in hemoglobinopathies: hydroxyurea (HU), erythropoietin (EPO), butyrate derivatives, blood substitutes].
    Bachir D; Galacteros F
    Transfus Clin Biol; 1994; 1(1):35-9. PubMed ID: 8186851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
    Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
    Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Klf10 Gene, a Secondary Modifier and a Pharmacogenomic Biomarker of Hydroxyurea Treatment Among Patients With Hemoglobinopathies.
    Elalfy MS; El Sherif NH; Kamal TM; Aly NH
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):e155-e162. PubMed ID: 28085748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.